Page 82 - Read Online

Page 12 of 14 Chia et al. Hepatoma Res 2019;5:9 I http://dx.doi.org/10.20517/2394-5079.2018.112

74. Tangkijvanich P, Chanmee T, Komtong S, Mahachai V, Wisedopas N, et al. Diagnostic role of serum glypican-3 in differentiating
hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. J Gastroenterol Hepatol 2010;25:129-37.
75. Jia X, Liu J, Gao Y, Huang Y, Du Z. Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma: a systematic
review with meta-analysis. Arch Med Res 2014;45:580-8.
76. Nakatsura T, Komori H, Kubo T, Yoshitake Y, Senju S, et al. Mouse homologue of a novel human oncofetal antigen, glypican-3,
evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res 2004;10:8630-40.
77. Motomura Y, Senju S, Nakatsura T, Matsuyoshi H, Hirata S, et al. Embryonic stem cell-derived dendritic cells expressing glypican-3,
a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10. Cancer Res
2006;66:2414-22.
78. Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, et al. Phase I trial of a glypican-3-derived peptide vaccine
for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res
2012;18:3686-96.
79. Gao H, Li K, Tu H, Pan X, Jiang H, et al. Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular
Carcinoma. Clin Cancer Res 2014;20:6418.
80. Zhai B, Shi D, Gao H, Qi X, Jiang H, et al. A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T)
in Chinese patients with refractory or relapsed GPC3+ hepatocellular carcinoma (r/r GPC3+ HCC). J Clin Oncol 2017;35:3049.
81. Ishiguro T, Sano Y, Komatsu SI, Kamata-Sakurai M, Kaneko A, et al. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody
for treatment of solid tumors. Sci Transl Med 2017;9:eaal4291.
82. Gessner R, Tauber R. Intestinal cell adhesion molecules. Liver-intestine cadherin. Ann N Y Acad Sci 2000;915:136-43.
83. Berndorff D, Gessner R, Kreft B, Schnoy N, Lajous-Petter AM, et al. Liver-intestine cadherin: molecular cloning and characterization
of a novel Ca2+-dependent cell adhesion molecule expressed in liver and intestine. J Cell Biol 1994;125:1353-69.
84. Dantzig AH, Hoskins JA, Tabas LB, Bright S, Shepard RL, et al. Association of intestinal peptide transport with a protein related to
the cadherin superfamily. Science 1994;264:430-3.
85. Wong BW, Luk JM, Ng IO, Hu MY, Liu KD, et al. Identification of liver-intestine cadherin in hepatocellular carcinoma--a potential
disease marker. Biochem Biophys Res Commun 2003;311:618-24.
86. Grotzinger C, Kneifel J, Patschan D, Schnoy N, Anagnostopoulos I, et al. LI-cadherin: a marker of gastric metaplasia and neoplasia.
Gut 2001;49:73-81.
87. Takamura M, Sakamoto M, Ino Y, Shimamura T, Ichida T, et al. Expression of liverintestine cadherin and its possible interaction with
galectin-3 in ductal adenocarcinoma of the pancreas. Cancer Sci 2003;94:425-30.
88. Wang XQ, Luk JM, Leung PP, Wong BW, Stanbridge EJ, et al. Alternative mRNA splicing of liver intestine-cadherin in hepatocellular
carcinoma. Clin Cancer Res 2005;11:483-9.
89. Takamura M, Ichida T, Matsuda Y, Kobayashi M, Yamagiwa S, et al. Reduced expression of liver-intestine cadherin is associated with
progression and lymph node metastasis of human colorectal carcinoma. Cancer Lett 2004;212:253-9.
90. Wong BW, Luk JM, Ng IO, Hu MY, Liu KD, et al. Identification of liver intestine cadherin in hepatocellular carcinoma - a potential
disease marker. Biochem Biophys Res Commun 2003;311:618-24.
91. Hinoi T, Lucas PC, Kuick R, Hanash S, Cho KR, et al. CDX2 regulates liver intestine-cadherin expression in normal and malignant
colon epithelium and intestinal metaplasia. Gastroenterology 2002;123:1565-77.
92. Park JH, Seol JA, Choi HJ, Roh YH, Choi PJ, et al. Comparison of cadherin-17 expression between primary colorectal
adenocarcinomas and their corresponding metastases: the possibility of a diagnostic marker for detecting the primary site of metastatic
tumour. Histopathology 2011;58:315-8.
93. Bartolome RA, Barderas R, Torres S, Fernandez-Acenero MJ, Mendes M, et al. Cadherin-17 interacts with a2b1 integrin to regulate
cell proliferation and adhesion in colorectal cancer cells causing liver metastasis. Oncogene 2014;33:1658-69.
94. Liu LX, Lee NP, Chan VW, Xue W, Zender L, et al. Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver
carcinoma. Hepatology 2009;50:1453-63.
95. Su MC, Yuan RH, Lin CY, Jeng YM. Cadherin-17 is a useful diagnostic marker for adenocarcinomas of the digestive system. Mod
Pathol 2008;21:1379-86.
96. Okada T, Kurabayashi A, Akimitsu N, Furihata M. Expression of cadherin-17 promotes metastasis in a highly bone marrow metastatic
murine breast cancer model. Biomed Res Int 2017;2017:8494286.
97. Bartolomé RA, Aizpurua C, Jaén M, Torres S, Calviño E, et al. Monoclonal antibodies directed against cadherin RGD exhibit
therapeutic activity against melanoma and colorectal cancer metastasis. Clin Cancer Res 2018;24:433-44.
98. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, et al. Identification and validation of oncogenes in liver cancer using an
integrative oncogenomic approach. Cell 2006;125:1253-67.
99. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, et al. Transforming properties of YAP, a candidate oncogene on the chromosome
11q22 amplicon. Proc Natl Acad Sci USA 2006;103:12405-10.
100. Morin-Kensicki EM, Boone BN, Howell M, Stonebraker JR, Teed J, et al. Defects in yolk sac vasculogenesis, chorioallantoic fusion,
and embryonic axis elongation in mice with targeted disruption of Yap65. Mol Cell Biol 2006;26:77-87.
101. Zhao B, Ye X, Yu J, Li L, Li W, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 2008;22:1962-71.
102. Dong J, Feldmann G, Huang J, Wu S, Zhang N, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals.
Cell 2007;130:1120-33.
103. Wu H, Liu Y, Jiang XW, Li WF, Guo G, et al. Clinicopathological and prognostic significance of Yes-associated protein expression in
hepatocellular carcinoma and hepatic cholangiocarcinoma. Tumour Biol 2016;37:13499-508.
104. Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, et al. Yes-associated protein is an independent prognostic marker in hepatocellular
carcinoma. Cancer 2009;115:4576-85.